Tomasz Burzykowski

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Positive Breast Cancer

Epidermal Growth Factor Receptor

Long Noncoding Rna

Top Venues

Pharmaceutical statistics

Current issues in molecular biology

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Kokot, Sachin Gadakh, Indrajit Saha, Ewa Gajda, Michał Łaźniewski, Somnath Rakshit, Kaustav Sengupta, Ayatullah Faruk Mollah, Michał Denkiewicz, Katarzyna Górczak, Jürgen Claesen, Tomasz Burzykowski, Dariusz Plewczyński
Unveiling the Molecular Mechanism of Trastuzumab Resistance in SKBR3 and BT474 Cell Lines for HER2 Positive Breast Cancer. Current issues in molecular biology 46 (3) (2024)
Anna Kokot, Sachin Gadakh, Indrajit Saha, Ewa Gajda, Michał Łaźniewski, Somnath Rakshit, Kaustav Sengupta, Ayatullah Faruk Mollah, Michał Denkiewicz, Katarzyna Górczak, Jürgen Claesen, Tomasz Burzykowski, Dariusz Plewczyński
Unveiling the Molecular Mechanism of Trastuzumab Resistance in SKBR3 and BT474 Cell Lines for HER2 Positive Breast Cancer. Current issues in molecular biology 46 (3) (2024)
Leandro Garcia Barrado, Tomasz Burzykowski
Using an early outcome as the sole source of information of interim decisions regarding treatment effect on a long-term endpoint: The non-Gaussian case. Pharmaceutical statistics (2024)
Anna Kokot, Sachin Gadakh, Indrajit Saha, Ewa Gajda, Michał Łaźniewski, Somnath Rakshit, Kaustav Sengupta, Ayatullah Faruk Mollah, Michał Denkiewicz, Katarzyna Górczak, Jürgen Claesen, Tomasz Burzykowski, Dariusz Plewczyński
Unveiling the Molecular Mechanism of Trastuzumab Resistance in SKBR3 and BT474 Cell Lines for HER2 Positive Breast Cancer. Current issues in molecular biology 46 (3) (2024)
Marc E Buyse, Everardo Delforge Saad, Tomasz Burzykowski, Meredith M Regan, Christopher S Sweeney
Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy. The oncologist 27 (4) (2022)
Tomasz Burzykowski
Semi-parametric accelerated failure-time model: A useful alternative to the proportional-hazards model in cancer clinical trials. Pharmaceutical statistics (2021)
Vaiva Deltuvaite-Thomas, Tomasz Burzykowski
Operational characteristics of generalized pairwise comparisons for hierarchically ordered endpoints. Pharmaceutical statistics (2021)